^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IDH1 R132

i
Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble
Entrez ID:
Related biomarkers:
1d
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1 (clinicaltrials.gov)
P2, N=15, Recruiting, Washington University School of Medicine | Trial completion date: Aug 2025 --> Jun 2026 | Trial primary completion date: Aug 2025 --> Jun 2026
Trial completion date • Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 R132
|
Tibsovo (ivosidenib)
14d
CL1-95032-005: Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Glioma (clinicaltrials.gov)
P1, N=72, Recruiting, Institut de Recherches Internationales Servier | Trial primary completion date: Mar 2024 --> Feb 2025
Trial primary completion date • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • ATRX (ATRX Chromatin Remodeler)
|
ATRX mutation • IDH1 R132H • IDH1 R132
|
Keytruda (pembrolizumab) • vorasidenib (S95032)
15d
Active site remodeling in tumor-relevant IDH1 mutants drives distinct kinetic features and potential resistance mechanisms. (PubMed, Nat Commun)
This active site remodeling reveals a possible mechanism of resistance to selective mutant IDH1 therapeutic inhibitors. This work enhances our understanding of fundamental IDH1 mechanisms while pinpointing regions for improving inhibitor selectivity.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • IDH1 R132H • IDH1 R132
20d
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma (clinicaltrials.gov)
P1, N=8, Terminated, Academic and Community Cancer Research United | Trial completion date: Jul 2025 --> Dec 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Dec 2023; Low accrual
Trial completion date • Trial termination • Trial primary completion date • Metastases
|
FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 R132C • IDH1 R132
|
cisplatin • gemcitabine • Pemazyre (pemigatinib) • Tibsovo (ivosidenib)
28d
Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation. (PubMed, J Med Chem)
Significantly, compound 23h has the ability to cross the blood-brain barrier (B/P ratio, 0.76) and demonstrates remarkable in vivo antitumor efficacy (20 mg/kg) in the U87 MG-IDH1R132H orthotopic transplantation mouse models without any notable toxicity. This proof-of-concept investigation substantiates the viability of discovering small molecules that concurrently target mIDH1 and NAMPT, providing valuable leads for the treatment of glioma and an efficient approach for the discovery of multitarget antitumor drugs.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NAMPT (Nicotinamide Phosphoribosyltransferase)
|
IDH1 mutation • IDH1 R132H • IDH1 R132
1m
Prognostic Value of ATRX and p53 Status in High-Grade Glioma Patients in Morocco. (PubMed, Cureus)
The clinical value of IDH and ATRX mutations in prognostic assessment was confirmed (p ≤0.05). The overexpression of p53 had no significant impact on OS (p = 0.726). Therefore, p53 alone cannot predict survival in glioblastoma patients. Based on the results, these biomarkers may be a potential therapeutic target to prolong patient survival, hence the need for further investigations.
Journal
|
TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • ATRX (ATRX Chromatin Remodeler)
|
TP53 mutation • IDH1 mutation • TP53 wild-type • ATRX mutation • IDH1 R132H • TP53 overexpression • IDH1 R132
2ms
Rapid IDH1-R132 genotyping panel utilizing locked nucleic acid loop-mediated isothermal amplification. (PubMed, Biol Methods Protoc)
The pH-based colorimetric indicator of LNA-LAMP facilitates convenient visual interpretation of reactions, and we demonstrate successful translation to an end-point format using absorbance ratio, allowing for an alternative and objective approach for differentiating between positive and negative reactions. Importantly, the LNA-LAMP genotyping panel is highly reproducible, with no false-positive or false-negative results observed.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 R132
2ms
Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma. (PubMed, JCO Precis Oncol)
Significant differences in GA and immune biomarkers are noted between IDH1/2+ and IDHwt iCCA. IDH1-/2-mutated tumors appear immunologically cold without gLOH. These immunogenomic data provide insight for precision targeting of iCCA with IDH alterations.
Journal • Retrospective data • Tumor mutational burden • PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • HRD (Homologous Recombination Deficiency) • PD-1 (Programmed cell death 1) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • CD70 (CD70 Molecule)
|
PD-L1 expression • MSI-H/dMMR • IDH1 mutation • HRD • VTCN1 underexpression • IDH1 R132C • IDH wild-type • IDH1 R132 • VTCN1 expression • IDH1 R132L • IDH2 R140 • IDH2 R172
|
PD-L1 IHC 22C3 pharmDx
2ms
NSUN5/TET2-directed chromatin-associated RNA modification of 5-methylcytosine to 5-hydroxymethylcytosine governs glioma immune evasion. (PubMed, Proc Natl Acad Sci U S A)
Importantly, pharmacological blockage of DNA methylation or IDH1-R132H mutant and CD47/SIRPα signaling synergistically enhances TAM-based phagocytosis and glioma elimination in vivo. Our findings unveil a general mechanism by which NSUN5/TET2/RBFOX2 signaling regulates RNA metabolism and highlight NSUN5 targeting as a potential strategy for glioma immune therapy.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha) • NSUN5 (NOP2/Sun RNA Methyltransferase 5)
|
IDH1 R132H • IDH1 R132
2ms
Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations. (PubMed, Pharmaceuticals (Basel))
The U.S. Food and Drug Administration (FDA) approved Ivosidenib, a molecular entity that targets IDH1 with R132 mutations, as a promising therapeutic option for AML with mIDH1 in 2018...RMSD showed that the four dynamics simulation systems remained stable, and RMSF and Rg showed that the screened molecules have similar local flexibility and tightness to the positive drug. Finally, the lowest energy conformation, hydrogen bond analysis, and free energy decomposition results indicate that in the entire system the key residues LEU120, TRP124, TRP267, and VAL281 mainly contribute van der Waals forces to the interaction, while the key residues VAL276 and CYS379 mainly contribute electrostatic forces.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • IDH1 R132C • IDH1 R132 • IDH1 R132C + IDH1 S280F
|
Tibsovo (ivosidenib)
2ms
Electrochemical Nanoreactor Provides a Comprehensive View of Isocitrate Dehydrogenase Cancer-drug Kinetics. (PubMed, Angew Chem Weinheim Bergstr Ger)
Ivosidenib, used to treat acute myeloid leukemia, acts on a common cancer-linked variant of isocitrate dehydrogenase 1 (IDH1 R132H) inhibiting its "gain-of-function" activity-the undesired reduction of 2-oxoglutarate (2OG) to the oncometabolite 2-hydroxyglutarate (2HG)...Such details, essential for understanding inhibition mechanisms, are not readily resolved in conventional steady-state kinetics or by techniques that rely only on measuring binding. Extending the new method and analytical framework presented here to other enzyme systems will be straightforward and should rapidly reveal insight that is difficult or often impossible to obtain using other methods.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH1 R132H • IDH1 R132
|
Tibsovo (ivosidenib)
2ms
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
P2, N=30, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 R132
|
Tibsovo (ivosidenib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
2ms
NRG-BN007: Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma (clinicaltrials.gov)
P2/3, N=147, Active, not recruiting, National Cancer Institute (NCI) | N=485 --> 147 | Trial completion date: Aug 2024 --> Mar 2025 | Trial primary completion date: Aug 2024 --> Apr 2023
Enrollment change • Trial completion date • Trial primary completion date • Tumor mutational burden
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
PD-L1 expression • MGMT promoter methylation • IDH1 R132H • IDH1 R132 • MGMT expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • ABP 206 (nivolumab biosimilar)
3ms
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 R132
3ms
The Idyllaâ„¢ IDH1-2 Mutation Assay Kit: A tool for mutation detection in IDH1 and IDH2 genes (AACR 2024)
With advancements in molecular diagnostics and precision therapy, IDH inhibitors such as ivosidenib, vorasidenib and enasidenib are now mainstay in management of patients with a susceptible mutation. The Idyllaâ„¢ IDH1-2 Mutation Assay Kit (RUO) is a fully automated qPCR assay for the qualitative detection of 15 common mutations in IDH1 (R132C/H/G/S/L) and IDH2 (R140Q/L/G/W, R172K/M/G/W/S) at codon level. The Idyllaâ„¢ IDH1-2 Mutation Assay Kit demonstrates a high concordance with established reference methods across a range of different specimen types.
KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH1 mutation • IDH2 mutation • KIT mutation • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH2 R140Q • IDH2 R140 • IDH2 R172
|
Idylla™ IDH1-2 Mutation Assay
|
Tibsovo (ivosidenib) • Idhifa (enasidenib) • vorasidenib (S95032)
3ms
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma (clinicaltrials.gov)
P1, N=49, Active, not recruiting, Institut de Recherches Internationales Servier | Trial completion date: May 2024 --> May 2025
Trial completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • ATRX (ATRX Chromatin Remodeler)
|
ATRX mutation • IDH1 R132H • IDH1 R132
|
Tibsovo (ivosidenib) • vorasidenib (S95032)
3ms
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations (clinicaltrials.gov)
P1, N=166, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Oct 2024 --> Oct 2025
Trial completion date • Metastases
|
IDH1 R132
|
IDH305
3ms
Genetic mutation patterns among glioblastoma patients in the Taiwanese population - insights from a single institution retrospective study. (PubMed, Cancer Gene Ther)
In Taiwanese GBM patients, bevacizumab usage is linked to improved survival rates, affirming its safety and effectiveness...TP53 mutations are associated with enhanced survival, but their functional implications necessitate detailed exploration. This study pioneers genetic analysis in Taiwanese GBM patients using NGS, advancing our understanding of their genetic landscape.
Retrospective data • Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CHEK2 (Checkpoint kinase 2)
|
TP53 mutation • EGFR mutation • CHEK2 mutation • IDH1 R132H • EGFR mutation + EGFR amplification • IDH1 R132
|
Avastin (bevacizumab)
3ms
Trial completion • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 R132 • Chr t(15;17)
|
cytarabine • azacitidine • Rezlidhia (olutasidenib)
3ms
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH (clinicaltrials.gov)
P1, N=75, Recruiting, Hutchmed | Trial completion date: Sep 2023 --> Jun 2025 | Trial primary completion date: Sep 2023 --> Sep 2024
Trial completion date • Trial primary completion date • Metastases
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH2 R140Q • IDH2 R172
|
HMPL-306
3ms
EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor. (PubMed, Cells)
We also found that, although the histone deacetylase inhibitor (HDACi) Panobinostat was less cytotoxic in IDH1R132H-mutated cells (either isolated from murine glioma or oligodendrocyte progenitor cells infected in vitro with a retrovirus expressing IDH1R132H) compared to IDH1-wild-type cells, combination treatment with Tazemetostat is synergistic in both mutant and wild-type models. These findings indicate a novel therapeutic strategy for IDH1-mutated gliomas that targets the specific epigenetic alteration in these tumors.
Journal • Epigenetic controller
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • IDH1 R132H • IDH wild-type • IDH1 R132
|
Tazverik (tazemetostat) • Farydak (panobinostat)
3ms
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (clinicaltrials.gov)
P1/2, N=60, Completed, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Suspended --> Completed
Trial completion
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH1 R132 • IDH2 R140 • IDH2 R172
|
temozolomide • Partruvix (pamiparib)
4ms
Evaluation of Immunohistochemical Expression of ALK-1 in Gliomas, WHO Grade 4 and Its Correlation with IDH1-R132H Mutation Status. (PubMed, Asian Pac J Cancer Prev)
GBs with detectable ALK-protein expression could potentially experience substantial clinical advantages through the utilization of newly introduced ALK inhibitors allowing personalized treatment to a subset of patients. Hence, future studies targeting ALK in IDH wildtype Glioblastomas including clinical trials on larger scales are recommended.
Journal
|
ALK (Anaplastic lymphoma kinase) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
ALK mutation • IDH1 R132H • IDH wild-type • IDH1 R132
4ms
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations (clinicaltrials.gov)
P2, N=145, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Enrollment closed
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G
|
Lynparza (olaparib)
4ms
IDH1 mutation predicts seizure occurrence and prognosis in lower-grade glioma adults. (PubMed, Pathol Res Pract)
Additionally, IDH1 R132H mutation predicted higher seizure-free ratios in LGG patients with intact ATRX expression (OR = 6.793, 95%CI = 1.217 - 37.923, P = 0.029) one year after diagnosis. Therefore, our findings suggest that IDH1 mutation can predict seizure occurrence and control in LGG patients, providing further insights into the relationship between glioma and epilepsy.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • ATRX (ATRX Chromatin Remodeler)
|
IDH1 mutation • IDH1 R132H • IDH1 R132
4ms
Giant skull base periosteal chondroma treated with endonasal endoscopic surgery: illustrative case. (PubMed, J Neurosurg Case Lessons)
This is the first known report of skull base periosteal chondroma. Genetic testing was useful for confirming the diagnosis, and EES was effective for treatment. Should such a tumor show adhesion to an important structure, an intracapsular excision can be beneficial for avoiding complications.
Journal • Surgery
|
TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • KDR (Kinase insert domain receptor)
|
IDH1 R132C • IDH1 R132 • KDR Q472H
4ms
Diagnostics of IDH1/2 Mutations in Intracranial Chondroid Tumors: Comparison of Molecular Genetic Methods and Immunohistochemistry. (PubMed, Diagnostics (Basel))
No IDH2 mutations were found. The use of independent diagnostic methods may improve the detection of IDH-mutant specimens in chondroid tumors.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH1 mutation • IDH2 mutation • IDH1 R132H • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH1 R132L • IDH1 R132S
4ms
Genetic profiling of rat gliomas and cardiac schwannomas from life-time radiofrequency radiation exposure study using a targeted next-generation sequencing gene panel. (PubMed, PLoS One)
The rat gliomas appear to share some genetic alterations with IDH1 wildtype human gliomas and rat cardiac schwannomas also harbor mutations in some of the queried cancer genes. These data demonstrate that targeted NGS panels based on tumor specific orthologous human cancer driver genes are an important tool to examine the translational relevance of rodent tumors resulting from chronic/life-time rodent bioassays.
Preclinical • Journal • Next-generation sequencing
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type • IDH1 R132 • IDH2 R172
4ms
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. (PubMed, Blood)
These neo-T cells could selectively recognize and kill HLA-matched AML targets endogenously expressing IDH2R140Q both in vitro and in vivo. Overall, our findings support the clinical translation of neoantigen-specific T cells to treat R/R AML.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
IDH1 R132 • IDH2 R140Q
4ms
Reliable detection of genetic alterations in cyst fluid DNA for the diagnosis of brain tumors. (PubMed, J Neurooncol)
Cell-free DNA obtained from cyst fluid in cystic brain tumors is a reliable alternative to tumor DNA when diagnosing brain tumors.
Journal
|
EGFR (Epidermal growth factor receptor) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase)
|
EGFR amplification • IDH1 R132H • TERT mutation • IDH1 R132 • TERT promoter mutation
4ms
rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide (clinicaltrials.gov)
P1/2, N=70, Recruiting, Washington University School of Medicine | Trial completion date: Jan 2030 --> Jan 2032 | Trial primary completion date: Jan 2030 --> Jan 2032
Trial completion date • Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
|
IDH1 R132H • IDH wild-type • IDH1 R132
|
temozolomide • Hyleukin-7 (efineptakin alfa)
4ms
IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients. (PubMed, BMC Cancer)
The present study demonstrates that liquid biopsy may be used in brain tumors to detect IDH1 mutation which represents an important prognostic biomarker in patients with different types of gliomas, being associated to OS.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • IDH1 R132H • IDH1 R132
4ms
Enrollment open
|
BRAF (B-raf proto-oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
BRAF mutation • IDH1 R132H • IDH1 R132
|
carboplatin • temozolomide • lomustine
5ms
Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone? (PubMed, Clin Orthop Relat Res)
We found that IDH1 R132 mutations were negatively associated with the prognosis of patients with bone chondrosarcomas. Nevertheless, more extensive studies (such as multicenter international studies) are needed and advisable to confirm our observations in this preliminary small series. Moreover, evaluating mutational status in fresh samples instead of in paraffin-embedded sections could help to increase the number of patients with adequate DNA for analysis. If our findings will be confirmed, the evaluation of IDH mutational status in biopsy samples or resection specimens could be considered when stratifying patients, highlighting those who may benefit from more aggressive treatment (such as adjuvant chemotherapy) or closer follow-up.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type • IDH1 R132 • IDH2 R172
5ms
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 R132C • IDH1 R132
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Tibsovo (ivosidenib)
5ms
Trial completion date • Trial primary completion date • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 R132 • Chr t(15;17)
|
cytarabine • azacitidine • Rezlidhia (olutasidenib)
5ms
Trial completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • SSR3 (Signal Sequence Receptor Subunit 3)
|
IDH1 R132H • IDH wild-type • IDH1 R132
|
carboplatin • albumin-bound paclitaxel
5ms
Optimization of a Protocol for Isolating Cell-free DNA from Cerebrospinal Fluid. (PubMed, Ann Lab Med)
MB isolation had a higher yield than CB isolation (P<0.0001), and post-isolation vacuum increased the final concentration in both methods, with little effect on cfDNA integrity. Our study provides a protocol to maximize CSF-ctDNA concentrations in IVD testing and future studies.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 R132C • IDH1 R132
5ms
A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma (clinicaltrials.gov)
P2, N=25, Active, not recruiting, Daiichi Sankyo Co., Ltd. | Trial primary completion date: Sep 2023 --> Mar 2023
Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation • IDH1 R132
|
safusidenib (AB-218)
5ms
The development of a hiPSC-based platform to identify tissue-dependencies of IDH1 R132H. (PubMed, Cell Death Discov)
Taken together, we provide proof for the potential of our sCSC technology as a potent addition to biomarker-driven drug development projects or studies on tumor therapy resistance. Moreover, follow-up projects such as comparing in vitro drug sensitivity profiles of hiPSC-derived tissue progenitors of different lineages, might help to understand a variety of tissue-related functions of IDH1 mutations.
Journal
|
TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
TP53 mutation • IDH1 mutation • IDH1 R132H • IDH1 R132
6ms
Phase classification • Metastases
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 R132H • IDH1 R132C • IDH1 R132 • IDH1 R132G • IDH1 R132L • IDH1 R132S
|
Tibsovo (ivosidenib)
6ms
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations (clinicaltrials.gov)
P1/2, N=60, Suspended, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Oct 2023 --> Dec 2023 | Trial primary completion date: Oct 2023 --> Dec 2023
Trial completion date • Trial primary completion date
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH1 R132 • IDH2 R140 • IDH2 R172
|
temozolomide • Partruvix (pamiparib)